Paris, France – September 2024 – Plantibodies has been selected to join the prestigious Endless Frontier Labs (EFL) program at NYU Stern School of Business, entering the Life Sciences Track.
EFL is a highly competitive, nine-month program that connects the most promising science-based startups from around the world with seasoned mentors, investors, and industry leaders in the U.S. The program is designed to accelerate scale-up and fundraising while refining business strategy and global positioning.
Plantibodies’ selection highlights the company’s potential to transform biologics delivery with its colon-targeted oral platform using plant-based biomanufacturing and natural bioencapsulation.
“Joining Endless Frontier Labs is a major milestone for Plantibodies,” said Pierre Bauër, CEO and co-founder. “It opens the door to world-class mentorship, access to U.S. biotech investors, and the opportunity to showcase our innovation on the global stage.”
Through the Life Sciences Track, Plantibodies will work closely with experts in biotech, pharma, venture capital, and regulatory affairs, furthering its mission to bring safer, more accessible therapies for gastrointestinal diseases to patients worldwide.